May 04, 2021 9:00am EDT QSAM Biosciences Announces Submission of IND Application for CycloSam® with FDA
Apr 28, 2021 9:00am EDT QSAM Biosciences Appoints Richard K. Burt, M.D., Pioneer in the Use of Stem Cell Transplants to Treat Autoimmune Diseases, to Scientific Board of Advisors
Apr 19, 2021 9:00am EDT QSAM Biosciences Issues Letter from CEO on Successful Achievements and Future Milestones for Company
Mar 17, 2021 9:00am EDT QSAM Biosciences Seeks to Expand Radiochemical Assets; Signs Option Agreement to License its Second Promising Cancer Therapy
Feb 16, 2021 9:00am EST QSAM Biosciences Appoints Charles J. Link, Jr., M.D., Experienced Biotech Executive and Innovator, to Board of Directors
Feb 11, 2021 6:08pm EST QSAM Biosciences Clarifies Recent Promotional and Trading Activities at the Request of OTC Markets
Jan 21, 2021 9:00am EST QSAM Biosciences Receives Favorable Safety Results in Study for its Leading Radiopharmaceutical Drug Candidate
Dec 10, 2020 9:00am EST QSAM Biosciences Receives Notice of Allowance for European Patent and Expands Licensed IP Portfolio
Nov 24, 2020 9:00am EST QSAM Biosciences Issues Letter from New CEO; Presents Opportunities Ahead for Company